The female figure as the antagonist in the arthurian world : the role of Morgan le Fay in Thomas Malory's Morte Darthur

In his Le Morte Darthur (1485), Malory took previous Arthurian myths and compiled them in one volume, adapting them so as to satisfy the values of his time. These changes and values can be seen in the case of the female figures, and specifically in the figure of Morgan le Fay. This paper studies the role of Morgan le Fay as the antagonist in Le Morte Darthur and how she becomes an active character from the marginality of her position; analyzing also whether her position as an active woman is, precisely, what puts her in the margins.En Le Morte Darthur (1485), Malory va agafar mites artúrics anteriors i els va recopilar en un volum, adaptant-los per a satisfer els valors del seu temps. Aquests canvis i valors es poden observar en el cas de les figures femenines, i específicament en la figura de Morgan le Fay. Aquest treball estudia el paper de la Morgan le Fay com a antagonista a Le Morte Darthur i de com ella es converteix en un personatge actiu des de la marginalitat de la seva posició; analitzant també si és precisament la seva posició com a dona activa la que la posa en els marges

Violencia de género: tratamiento y prevención

Esta publicación ha sido posible gracias a la V Convocatoria de Ayudas para Proyectos de Cooperación al Desarrollo y Apoyo a la Movilidad de la Universidad Carlos III de Madrid.Introducción / Helena Soleto Muñoz (pp. 11-12). -- Rocío Zafra Espinosa de los Monteros / Situación general de la violencia de género en España (pp. 13-35). -- María Ángeles Carmona / Violencia de género: prevención y abordaje en justicia (pp. 37-50). -- Belén Hernández Moura / Protección de las víctimas de violencia de género en la ley 4/2015 (pp. 51-73). -- Cristina Ruiz López / La denuncia del delito de violencia de género: perspectivas interrelacionadas (pp. 75-101). -- Félix Arias / Aproximación a la violencia de género desde una perspectiva psicológica (pp. 103-130). -- Santiago Madrid Liras / Dinámica y aspectos psicológicos en las relaciones de maltrato: la “tela de araña” (pp. 131-158). -- Emiliano Carretero Morales / Utilidad de los ODR en los casos de violencia de género (pp. 159-190). -- Cómic / Helena Soleto Muñoz, Jessica Jullien de Asís y Andrea Ochaita Calvo (pp. 191-212). -- Los autores (pp. 213)

Charming and bewitching : considering the Harry Potter series

Aquest document està relacionat amb: Addictive and wonderful : the experience of reading the Harry Potter serie

Addictive and wonderful : the experience of reading the Harry Potter series

Aquest document està relacionat amb: Charming and bewitching : considering the Harry Potter serie

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients : the SOLID study

At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. ClinicalTrials.gov identifier: NCT04407143

Down syndrome as risk factor for respiratory syncytial virus hospitalization : A prospective multicenter epidemiological study

Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality. To compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection. In a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season. The hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively. Infants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered

Make EU trade with Brazil sustainable

Brazil, home to one of the planet's last great forests, is currently in trade negotiations with its second largest trading partner, the European Union (EU). We urge the EU to seize this critical opportunity to ensure that Brazil protects human rights and the environment